RRC ID 71813
Author Hamamoto H, Panthee S, Paudel A, Ishii K, Yasukawa J, Su J, Miyashita A, Itoh H, Tokumoto K, Inoue M, Sekimizu K.
Title Serum apolipoprotein A-I potentiates the therapeutic efficacy of lysocin E against Staphylococcus aureus.
Journal Nat Commun
Abstract Lysocin E is a lipopeptide with antibiotic activity against methicillin-resistant Staphylococcus aureus. For unclear reasons, the antibacterial activity of lysocin E in a mouse systemic infection model is higher than expected from in vitro results, and the in vitro activity is enhanced by addition of bovine serum. Here, we confirm that serum from various species, including humans, increases lysocin E antimicrobial activity, and identify apolipoprotein A-I (ApoA-I) as an enhancing factor. ApoA-I increases the antibacterial activity of lysocin E when added in vitro, and the antibiotic displays reduced activity in ApoA-I gene knockout mice. Binding of ApoA-I to lysocin E is enhanced by lipid II, a cell-wall synthesis precursor found in the bacterial membrane. Thus, the antimicrobial activity of lysocin E is potentiated through interactions with host serum proteins and microbial components.
Volume 12(1)
Pages 6364
Published 2021-11-4
DOI 10.1038/s41467-021-26702-0
PII 10.1038/s41467-021-26702-0
PMID 34737305
PMC PMC8568920
MeSH Animals Anti-Bacterial Agents / pharmacology* Apolipoprotein A-I / blood* Disease Models, Animal Female Lipopeptides / pharmacology Methicillin-Resistant Staphylococcus aureus / drug effects* Methicillin-Resistant Staphylococcus aureus / isolation & purification Mice Mice, Inbred C57BL Mice, Inbred ICR Microbial Sensitivity Tests Peptides, Cyclic / pharmacology* Staphylococcal Infections / blood Staphylococcal Infections / drug therapy* Staphylococcal Infections / microbiology
IF 12.121
Resource
Silkworms